Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

BACKGROUND: Pulmonary hypertension patients experienced a high financial burden due to the high cost of drug therapy, high incidence of comorbidities and hospitalizations. Endothelin receptor antagonists (ERAs) in PAH treatment showed a high cost. While ambrisentan has been covered by medical insura...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jingyuan, Luo, Jun, Yang, Xiaojie, Luo, Peng, Chen, Yusi, Li, Zilu, Li, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165300/
https://www.ncbi.nlm.nih.gov/pubmed/34079351
http://dx.doi.org/10.2147/IJGM.S304992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165300/
https://www.ncbi.nlm.nih.gov/pubmed/34079351
http://dx.doi.org/10.2147/IJGM.S304992

Ejemplares similares